Sergey Cheporov

1.2k total citations
28 papers, 588 citations indexed

About

Sergey Cheporov is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sergey Cheporov has authored 28 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Sergey Cheporov's work include Cancer Treatment and Pharmacology (16 papers), Colorectal Cancer Treatments and Studies (9 papers) and HER2/EGFR in Cancer Research (6 papers). Sergey Cheporov is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Colorectal Cancer Treatments and Studies (9 papers) and HER2/EGFR in Cancer Research (6 papers). Sergey Cheporov collaborates with scholars based in Russia, United States and United Kingdom. Sergey Cheporov's co-authors include G. Manikhas, Paul Bhar, А. Н. Махсон, D. Krasnojon, Alicia Clawson, William J. Gradishar, José Iglesias, John R. McGuire, Mark A. Socinski and С. В. Орлов and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sergey Cheporov

25 papers receiving 575 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sergey Cheporov Russia	8	495	188	158	64	47	28	588
G. Manikhas Russia	10	536 1.1×	197 1.0×	229 1.4×	122 1.9×	45 1.0×	25	681
D. Ilegbodu United States	12	574 1.2×	162 0.9×	181 1.1×	105 1.6×	17 0.4×	30	711
D. Krasnojon Russia	5	348 0.7×	160 0.9×	77 0.5×	30 0.5×	40 0.9×	9	396
F. Nolè Italy	7	467 0.9×	269 1.4×	163 1.0×	235 3.7×	17 0.4×	12	686
Karel Cwiertka Czechia	10	247 0.5×	108 0.6×	123 0.8×	115 1.8×	35 0.7×	45	436
V. Georgoulias Greece	16	843 1.7×	375 2.0×	267 1.7×	275 4.3×	33 0.7×	38	1.0k
M. Decatris United Kingdom	12	240 0.5×	72 0.4×	116 0.7×	146 2.3×	52 1.1×	19	505
D. Bafaloukos Greece	13	566 1.1×	112 0.6×	185 1.2×	191 3.0×	37 0.8×	37	777
Kaori Fujimoto-Ouchi United States	15	552 1.1×	101 0.5×	283 1.8×	242 3.8×	11 0.2×	28	823
D. Tsavdaridis Greece	12	612 1.2×	109 0.6×	358 2.3×	109 1.7×	16 0.3×	27	722

Countries citing papers authored by Sergey Cheporov

Since Specialization

Citations

This map shows the geographic impact of Sergey Cheporov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergey Cheporov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergey Cheporov more than expected).

Fields of papers citing papers by Sergey Cheporov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergey Cheporov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergey Cheporov. The network helps show where Sergey Cheporov may publish in the future.

Co-authorship network of co-authors of Sergey Cheporov

This figure shows the co-authorship network connecting the top 25 collaborators of Sergey Cheporov. A scholar is included among the top collaborators of Sergey Cheporov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergey Cheporov. Sergey Cheporov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheporov, Sergey, et al.. (2023). The choice of treatment for chemorefractory colon cancer. Malignant tumours. 13(3). 56–63.

Cheporov, Sergey, et al.. (2023). Systemic therapy of skin metastatic melanoma with BRAF gene mutation. SHILAP Revista de lepidopterología. 10(1). 27–35. 1 indexed citations

Султанбаев, А. В., et al.. (2023). Pharmacotherapy regimens for patients with hormone-receptor positive (HR+), human epidermal growth factor 2 negative (HER2–) metastatic breast cancer in routine clinical practice (results of non-interventional retrospective study). Medical alphabet. 7–14.

Cheporov, Sergey, et al.. (2023). Evaluation of Overall Survival Rate of Patients with Metastatic Colorectal Cancer Depending on Choice of Treatment, Location of Primary Focus and RAS Genes Mutation Status. I P Pavlov Russian Medical Biological Herald. 31(1). 109–118.

Тихомирова, И. А., et al.. (2016). Alteration of red blood cell microrheology by anti-tumor chemotherapy drugs. Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology. 10(2). 135–141. 3 indexed citations

Tjulandin, Sergei, Sergey Cheporov, Vladimir Vladimirov, et al.. (2016). Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC). Annals of Oncology. 27. vi123–vi123. 3 indexed citations

Tannir, Nizar M., Thomas Powles, Robert J. Motzer, et al.. (2016). Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). Annals of Oncology. 27. vi285–vi285. 1 indexed citations

Tabernero, Josep, Rocio García‐Carbonero, James T. Cassidy, et al.. (2013). Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clinical Cancer Research. 19(9). 2541–2550. 69 indexed citations

Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2012). Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival. Clinical Breast Cancer. 12(5). 313–321. 91 indexed citations

10.

Buzdar, Aman U., Binghe Xu, Raghunadharao Digumarti, et al.. (2011). Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Annals of Oncology. 23(3). 589–597. 11 indexed citations

11.

Socinski, Mark A., G. Manikhas, А. Н. Махсон, et al.. (2010). A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(6). 852–861. 67 indexed citations

12.

Muravyov, A. V., et al.. (2010). Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients. Clinical Hemorheology and Microcirculation. 44(2). 115–123. 6 indexed citations

13.

Muravyov, A. V., et al.. (2009). Hemorheological changes in solid tumor patients after treatment with recombinant erythropoetin. Clinical Hemorheology and Microcirculation. 41(1). 39–47. 7 indexed citations

14.

Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2009). Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 27(22). 3611–3619. 260 indexed citations

15.

Gradishar, WJ, D. Krasnojon, Sergey Cheporov, et al.. (2008). Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC). European Journal of Cancer Supplements. 6(7). 172–172. 6 indexed citations

16.

Karlin, David A., Sergey Cheporov, Oleg Gladkov, et al.. (2008). First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC). Journal of Clinical Oncology. 26(15_suppl). 4100–4100. 3 indexed citations

17.

Earhart, Robert H., Sergey Cheporov, Oleg Gladkov, et al.. (2008). 210 POSTER Preliminary results of a Phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing first-line therapy for colorectal cancer (CRC). European Journal of Cancer Supplements. 6(12). 67–67. 1 indexed citations

18.

Hawkins, Michael, G. Manikhas, А. Н. Махсон, et al.. (2007). Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7659–7659. 5 indexed citations

19.

Krasnojon, D., et al.. (2007). 2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer. European Journal of Cancer Supplements. 5(4). 215–215. 2 indexed citations

20.

Hawkins, Michael, et al.. (2006). Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 7132–7132. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact